NasdaqGS:DFTXPharmaceuticals
How Approaching DT120 Phase III Readouts At Definium Therapeutics (DFTX) Have Changed Its Investment Story
In recent days, Definium Therapeutics has drawn heightened attention as it nears three pivotal Phase III readouts for its lead brain health candidate DT120, a potential inflection point in its transition from research-focused to commercial-stage operations.
This growing focus on DT120’s late-stage data has sharpened debate over how successfully Definium’s psychedelic-based therapies might address unmet needs in large psychiatric markets such as generalized anxiety disorder and major...